237 related articles for article (PubMed ID: 28597356)
1. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
2. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
Zúñiga MA; Alderete JB; Jaña GA; Fernandez PA; Ramos MJ; Jiménez VA
Chem Biol Drug Des; 2018 May; 91(5):1042-1055. PubMed ID: 29316292
[TBL] [Abstract][Full Text] [Related]
3. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of microtubule stabilization by laulimalide and peloruside A.
Prota AE; Bargsten K; Northcote PT; Marsh M; Altmann KH; Miller JH; Díaz JF; Steinmetz MO
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1621-5. PubMed ID: 24470331
[TBL] [Abstract][Full Text] [Related]
5. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.
Khrapunovich-Baine M; Menon V; Yang CP; Northcote PT; Miller JH; Angeletti RH; Fiser A; Horwitz SB; Xiao H
J Biol Chem; 2011 Apr; 286(13):11765-78. PubMed ID: 21245138
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling study on the differential microtubule-stabilizing effect in singly- and doubly-bonded complexes with peloruside A and paclitaxel.
Zúñiga MA; Alderete JB; Jaña GA; Navarrete KR; Jiménez VA
Proteins; 2019 Aug; 87(8):668-678. PubMed ID: 30958582
[TBL] [Abstract][Full Text] [Related]
7. The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Aug; 86(2):190-9. PubMed ID: 25376845
[TBL] [Abstract][Full Text] [Related]
8. Docking and molecular dynamics studies of the binding between Peloruside A and tubulin.
Liao SY; Mo GQ; Chen JC; Zheng KC
J Enzyme Inhib Med Chem; 2014 Oct; 29(5):702-9. PubMed ID: 24156744
[TBL] [Abstract][Full Text] [Related]
9. Molecular recognition of peloruside A by microtubules. The C24 primary alcohol is essential for biological activity.
Pera B; Razzak M; Trigili C; Pineda O; Canales A; Buey RM; Jiménez-Barbero J; Northcote PT; Paterson I; Barasoain I; Díaz JF
Chembiochem; 2010 Aug; 11(12):1669-78. PubMed ID: 20665616
[TBL] [Abstract][Full Text] [Related]
10. A unique mode of microtubule stabilization induced by peloruside A.
Huzil JT; Chik JK; Slysz GW; Freedman H; Tuszynski J; Taylor RE; Sackett DL; Schriemer DC
J Mol Biol; 2008 May; 378(5):1016-30. PubMed ID: 18405918
[TBL] [Abstract][Full Text] [Related]
11. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.
Hamel E; Day BW; Miller JH; Jung MK; Northcote PT; Ghosh AK; Curran DP; Cushman M; Nicolaou KC; Paterson I; Sorensen EJ
Mol Pharmacol; 2006 Nov; 70(5):1555-64. PubMed ID: 16887932
[TBL] [Abstract][Full Text] [Related]
13. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
Kanakkanthara A; Northcote PT; Miller JH
Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
[TBL] [Abstract][Full Text] [Related]
14. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
15. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
[TBL] [Abstract][Full Text] [Related]
16. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
[TBL] [Abstract][Full Text] [Related]
17. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.
Nguyen TL; Xu X; Gussio R; Ghosh AK; Hamel E
J Chem Inf Model; 2010 Nov; 50(11):2019-28. PubMed ID: 21028850
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
[TBL] [Abstract][Full Text] [Related]
19. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV
J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
[TBL] [Abstract][Full Text] [Related]
20. Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease.
Kanakkanthara A; Northcote PT; Miller JH
Nat Prod Rep; 2016 Apr; 33(4):549-61. PubMed ID: 26867978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
